Similarly, in immunomodulatory regimens and platinum-based anti-cancer therapies, bacteria-associated TLR4 agonists were shown to modulate tumor necrosis factor (TNF)- and reactive oxygen species (ROS)-mediated anti-tumor effects of tumor-infiltrating myeloid-derived suppressor cells (MDSCs) [16]. Here, TNF is linked to cancer.